These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 28379469)

  • 1. In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome.
    Di Pietro M; Pascuali N; Scotti L; Irusta G; Bas D; May M; Tesone M; Abramovich D; Parborell F
    Mol Hum Reprod; 2017 Jun; 23(6):417-427. PubMed ID: 28379469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingosine-1-phosphate restores endothelial barrier integrity in ovarian hyperstimulation syndrome.
    Scotti L; Di Pietro M; Pascuali N; Irusta G; I de Zúñiga ; Gomez Peña M; Pomilio C; Saravia F; Tesone M; Abramovich D; Parborell F
    Mol Hum Reprod; 2016 Dec; 22(12):852-866. PubMed ID: 27645281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceramide-1-phosphate has protective properties against cyclophosphamide-induced ovarian damage in a mice model of premature ovarian failure.
    Pascuali N; Scotti L; Di Pietro M; Oubiña G; Bas D; May M; Gómez Muñoz A; Cuasnicú PS; Cohen DJ; Tesone M; Abramovich D; Parborell F
    Hum Reprod; 2018 May; 33(5):844-859. PubMed ID: 29534229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet-derived growth factor B restores vascular barrier integrity and diminishes permeability in ovarian hyperstimulation syndrome.
    Pascuali N; Scotti L; Oubiña G; de Zúñiga I; Gomez Peña M; Pomilio C; Saravia F; Tesone M; Abramovich D; Parborell F
    Mol Hum Reprod; 2020 Aug; 26(8):585-600. PubMed ID: 32467982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model.
    Quintana R; Kopcow L; Marconi G; Young E; Yovanovich C; Paz DA
    Fertil Steril; 2008 Oct; 90(4 Suppl):1511-6. PubMed ID: 18166186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5.
    Kitajima Y; Endo T; Nagasawa K; Manase K; Honnma H; Baba T; Hayashi T; Chiba H; Sawada N; Saito T
    Endocrinology; 2006 Feb; 147(2):694-9. PubMed ID: 16269461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect and underlying mechanism of Bu-Shen-An-Tai recipe on ovarian apoptosis in mice with controlled ovarian hyperstimulation implantation dysfunction.
    Ma WW; Xiao J; Song YF; Ding JH; Tan XJ; Song KK; Zhang MM
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):401-406. PubMed ID: 28585136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: an experimental study.
    Pala Ş; Atilgan R; Ozkan ZS; Kavak SB; Ilhan N; Akpolat N; Sapmaz E
    Drug Des Devel Ther; 2015; 9():1761-6. PubMed ID: 25848212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death.
    Li F; Turan V; Lierman S; Cuvelier C; De Sutter P; Oktay K
    Hum Reprod; 2014 Jan; 29(1):107-13. PubMed ID: 24221908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local VEGF inhibition prevents ovarian alterations associated with ovarian hyperstimulation syndrome.
    Scotti L; Abramovich D; Pascuali N; Irusta G; Meresman G; Tesone M; Parborell F
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():392-401. PubMed ID: 25151950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function.
    Owens LA; Abbara A; Lerner A; O'floinn S; Christopoulos G; Khanjani S; Islam R; Hardy K; Hanyaloglu AC; Lavery SA; Dhillo WS; Franks S
    Hum Reprod; 2018 Feb; 33(2):292-302. PubMed ID: 29206944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
    Şahin N; Apaydın N; Töz E; Sivrikoz ON; Genç M; Turan GA; Cengiz H; Eskicioğlu F
    Arch Gynecol Obstet; 2016 May; 293(5):1101-6. PubMed ID: 26690356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
    Kosmas IP; Kitsou C; Lazaros L; Markoula S; Peschos D; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos A; Galani V; Georgiou I
    Gynecol Endocrinol; 2015; 31(9):702-7. PubMed ID: 26172931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model.
    Hortu I; Karadadas E; Ozceltik G; Tavmergen E; Tavmergen Goker EN; Yigitturk G; Erbas O
    Arch Gynecol Obstet; 2021 Apr; 303(4):1099-1108. PubMed ID: 33140116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous neutralization of vascular endothelial growth factor reduces vascular function/permeability of the ovary and prevents development of OHSS-like symptoms in rhesus monkeys.
    Bishop CV; Lee DM; Slayden OD; Li X
    J Ovarian Res; 2017 Jul; 10(1):41. PubMed ID: 28683759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of resveratrol on ovarian hyperstimulation syndrome in a rat model.
    Ozgur S; Oktem M; Altinkaya SO; Oktem EO; Cenksoy C; Erdem O; Elbeg S; Helvaci A; Erdem A; Erdem M
    Taiwan J Obstet Gynecol; 2018 Jun; 57(3):383-388. PubMed ID: 29880170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.